FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:11-20 January 1, 2004 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Crumpacker, C. S. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV.

Methods We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic genital HSV-2 and one susceptible to HSV-2. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. Source partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2 mucosal shedding. Both partners were counseled on safer sex and were offered condoms at each visit. The predefined primary end point was the reduction in transmission of symptomatic genital herpes.

Results Clinically symptomatic HSV-2 infection developed in 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.08 to 0.75; P=0.008). Overall, acquisition of HSV-2 was observed in 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 percent) who received placebo (hazard ratio, 0.52; 95 percent confidence interval, 0.27 to 0.99; P=0.04). HSV DNA was detected in samples of genital secretions on 2.9 percent of the days among the HSV-2–infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days among those who received placebo (P<0.001). The mean rates of recurrence were 0.11 per month and 0.40 per month, respectively (P<0.001).

Conclusions Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2–discordant couples.

Source Information

From the Departments of Medicine (L.C., A.W.), Laboratory Medicine (L.C., R.A.M.), and Epidemiology (A.W.), University of Washington, Seattle; the Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle (L.C.); the Department of Genitourinary Medicine, Royal South Hants Hospital, Southampton, United Kingdom (R.P.); Viridae Clinical Sciences and University of British Columbia, Vancouver, Canada (S.L.S.); the University of Texas Medical Branch, Galveston (S.K.T.); Westover Heights Clinic, Portland, Oreg. (T.W.); the Disease Control Service, Denver Department of Public Health, Denver (J.M.D.); the Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland (J.P.); Dow Pharmaceutical Sciences and Department of Dermatology, University of California, San Francisco (K.R.B.); the Department of Clinical Pharmacology, Smolensk State Medical Academy, Smolensk, Russia (L.S.S.); the Department of Medicine, University of New Mexico, Albuquerque (G.M.); and the Departments of Biomedical Data Sciences (O.N.K.) and Antiviral Clinical Research (H.A.W., D.T., M.V.-C.), GlaxoSmithKline Research and Development, Greenford, United Kingdom.

Address reprint requests to Dr. Corey at the Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Rm. D3-100, P.O. Box 19024, Seattle, WA 98109, or at lcorey{at}u.washington.edu.

Full Text of this Article

This article has been cited by other articles:

• Cernik, C., Gallina, K., Brodell, R. T. (2008). The Treatment of Herpes Simplex Infections: An Evidence-Based Review. Arch Intern Med 168: 1137-1144 [Abstract] [Full Text]  
• Goldmeier, D., Garvey, L., Barton, S. (2008). Does chronic stress lead to increased rates of recurrences of genital herpes - a review of the psychoneuroimmunological evidence?. Int J STD AIDS 19: 359-362 [Abstract] [Full Text]  
• Koelle, D. M., Magaret, A., McClurkan, C. L., Remington, M. L., Warren, T., Teofilovici, F., Wald, A. (2008). Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects. CVI 15: 773-782 [Abstract] [Full Text]  
• Romanowski, B, Zdanowicz, Y M, Owens, S T (2008). In search of optimal genital herpes management and standard of care (INSIGHTS): doctors' and patients' perceptions of genital herpes. Sex. Transm. Infect. 84: 51-56 [Abstract] [Full Text]  
• Gardella, C., Barnes, J., Magaret, A. S., Richards, J., Drolette, L., Wald, A. (2007). Prenatal Herpes Simplex Virus Serologic Screening Beliefs and Practices Among Obstetricians. Obstet Gynecol 110: 1364-1370 [Abstract] [Full Text]  
• Freeman, E. E, Orroth, K. K, White, R. G, Glynn, J. R, Bakker, R., Boily, M.-C., Habbema, D., Buve, A., Hayes, R. (2007). Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex. Transm. Infect. 83: i17-i24 [Abstract] [Full Text]  
• Sen, P, Barton, S E (2007). Genital herpes and its management. BMJ 334: 1048-1052 [Full Text]  
• Bultmann, H., Teuton, J., Brandt, C. R. (2007). Addition of a C-Terminal Cysteine Improves the Anti-Herpes Simplex Virus Activity of a Peptide Containing the Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain. Antimicrob. Agents Chemother. 51: 1596-1607 [Abstract] [Full Text]  
• Magaret, A. S., Wald, A., Huang, M.-L., Selke, S., Corey, L. (2007). Optimizing PCR Positivity Criterion for Detection of Herpes Simplex Virus DNA on Skin and Mucosa. J. Clin. Microbiol. 45: 1618-1620 [Abstract] [Full Text]  
• Teuton, J. R., Brandt, C. R. (2007). Sialic Acid on Herpes Simplex Virus Type 1 Envelope Glycoproteins Is Required for Efficient Infection of Cells. J. Virol. 81: 3731-3739 [Abstract] [Full Text]  
• Nagot, N., Ouedraogo, A., Foulongne, V., Konate, I., Weiss, H. A., Vergne, L., Defer, M.-C., Djagbare, D., Sanon, A., Andonaba, J.-B., Becquart, P., Segondy, M., Vallo, R., Sawadogo, A., Van de Perre, P., Mayaud, P., the ANRS 1285 Study Group, (2007). Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus. NEJM 356: 790-799 [Abstract] [Full Text]  
• Paz-Bailey, G, Ramaswamy, M, Hawkes, S J, Geretti, A M (2007). Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex. Transm. Infect. 83: 16-22 [Abstract] [Full Text]  
• Geretti, A M (2006). Genital herpes. Sex. Transm. Infect. 82: iv31-iv34 [Full Text]  
• Tita, A. T. N., Grobman, W. A., Rouse, D. J. (2006). Antenatal herpes serologic screening: an appraisal of the evidence.. Obstet Gynecol 108: 1247-1253 [Abstract] [Full Text]  
• Williams, J R, Foss, A M, Vickerman, P, Watts, C, Ramesh, B M, Reza-Paul, S, Washington, R G, Moses, S, Blanchard, J, Lowndes, C M, Alary, M, Boily, M-C (2006). What is the achievable effectiveness of the India AIDS Initiative intervention among female sex workers under target coverage? Model projections from southern India.. Sex. Transm. Infect. 82: 372-380 [Abstract] [Full Text]  
• Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. M., Markowitz, L. E. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.. JAMA 296: 964-973 [Abstract] [Full Text]  
• Sheffield, J. S., Hill, J. B., Hollier, L. M., Laibl, V. R., Roberts, S. W., Sanchez, P. J., Wendel, G. D. Jr (2006). Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.. Obstet Gynecol 108: 141-147 [Abstract] [Full Text]  
• Rosenthal, S L, Zimet, G D, Leichliter, J S, Stanberry, L R, Fife, K H, Tu, W, Bernstein, D I (2006). The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection.. Sex. Transm. Infect. 82: 154-157 [Abstract] [Full Text]  
• Rana, R K, Pimenta, J M, Rosenberg, D M, Warren, T, Sekhin, S, Cook, S F, Robinson, N J, on behalf of the Valaciclovir HSV Transmission Stu, (2006). Sexual behaviour and condom use among individuals with a history of symptomatic genital herpes. Sex. Transm. Infect. 82: 69-74 [Abstract] [Full Text]  
• Bartlett, J. G. (2006). Update in Infectious Diseases. ANN INTERN MED 144: 49-56 [Full Text]  
• Pickering, J M, Whitworth, J A G, Hughes, P, Kasse, M, Morgan, D, Mayanja, B, Van der Paal, L, Mayaud, P (2005). Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sex. Transm. Infect. 81: 488-493 [Abstract] [Full Text]  
• Wald, A., Langenberg, A. G.M., Krantz, E., Douglas, J. M. Jr, Handsfield, H. H., DiCarlo, R. P., Adimora, A. A., Izu, A. E., Morrow, R. A., Corey, L. (2005). The Relationship between Condom Use and Herpes Simplex Virus Acquisition. ANN INTERN MED 143: 707-713 [Abstract] [Full Text]  
• Hook, E. W. III (2005). An Ounce of Prevention. ANN INTERN MED 143: 751-752 [Full Text]  
• Brown, Z. A., Gardella, C., Wald, A., Morrow, R. A., Corey, L. (2005). Genital Herpes Complicating Pregnancy. Obstet Gynecol 106: 845-856 [Abstract] [Full Text]  
• Gardella, C., Brown, Z. A., Wald, A., Morrow, R. A., Selke, S., Krantz, E., Corey, L. (2005). Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor. Obstet Gynecol 106: 268-274 [Abstract] [Full Text]  
• Meyer, J L, Crosby, R A, Whittington, W L H, Carrell, D, Ashley-Morrow, R, Meier, A S, Harrington, R D, DiClemente, R, Wald, A (2005). The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. Sex. Transm. Infect. 81: 309-315 [Abstract] [Full Text]  
• Fisman, D N (2005). Health related quality of life in genital herpes: a pilot comparison of measures. Sex. Transm. Infect. 81: 267-270 [Abstract] [Full Text]  
• Looker, K J, Garnett, G P (2005). A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex. Transm. Infect. 81: 103-107 [Abstract] [Full Text]  
• Barton, S. E (2005). Reducing the transmission of genital herpes. BMJ 330: 157-158 [Full Text]  
• Lindbaek, M. (2004). Valacyclovir reduced genital herpes transmission in couples discordant for herpes simplex virus type 2 infection. Evid. Based Med. 9: 146-146 [Full Text]  
• (2004). Other articles noted: 06 Feb 2004 to 16 Apr 2004. Evid. Based Nurs. 7: e3-e3 [Full Text]  
• MacDougall, C., Guglielmo, B. J. (2004). Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53: 899-901 [Abstract] [Full Text]  
• Kimberlin, D. W., Rouse, D. J. (2004). Genital Herpes. NEJM 350: 1970-1977 [Full Text]  
• (2004). Once-daily valacyclovir to reduce the risk of transmission of genital herpes. Obstet Gynecol 103: 797-797 [Full Text]  
• (2004). Once daily valcyclovir slightly reduces the risk of transmitting HSV-2 to uninfected partners. BMJ 328: - [Full Text]  
• (2004). Valacyclovir Prevents Sexual Transmission of HSV-2. JWatch Women's Health 2004: 1-1 [Full Text]  
• (2004). Blocking the Transmission of Genital Herpes with Daily Valacyclovir. Journal Watch Dermatology 2004: 6-6 [Full Text]  
• (2004). Daily Antiviral Therapy Reduces Transmission of Genital HSV. JWatch General 2004: 4-4 [Full Text]  
• Crumpacker, C. S. (2004). Use of Antiviral Drugs to Prevent Herpesvirus Transmission. NEJM 350: 67-68 [Full Text]